Abstract
Sublingual or Subcutaneous immunotherapy for Seasonal Allergic Rhinitis (AR): an indirect analysis of efficacy, safety and cost
Highlights
The current standard of preventive care for poorly controlled seasonal Allergic Rhinitis (AR) symptoms is subcutaneous immunotherapy (SCIT) with allergen extracts, administered in a physician’s office
A systematic review of major databases was conducted from January 1980 to December 2012 for double blind placebo controlled randomized trials evaluating OralairTM, GrazaxTM or SCIT in patients with grass-induced seasonal AR
Other variables considered in the regression model included year of study publication, geographic region where the trial was conducted, trial duration, duration of immunotherapy, number of asthmatic patients enrolled in the trial, number of allergens and patient type
Summary
The current standard of preventive care for poorly controlled seasonal AR symptoms is subcutaneous immunotherapy (SCIT) with allergen extracts, administered in a physician’s office. As an alternative to SC administration, sublingual immunotherapy (SLIT) is an option for patients. OralairTM and GrazaxTM are two SLIT agents currently available in many countries. Head to head comparative data between the three options are not available. An indirect comparison on efficacy, safety and cost was undertaken between OralairTM, GrazaxTM and SCIT
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
